ArticleDrug design, development and therapy2025
Potential Cardiovascular Risks Associated with Naltrexone-Bupropion Treatment in Overweight Patients [Response to Letter].
Young Sang Lyu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.